Genopole, the biocluster located in the Greater Paris region is the first European park to receive the Association of University Research Parks (AURP) award. This is the first time a member outside the US has been acknowledged. The announcement was made during AURP’s International Annual Conference in Baltimore (Maryland).
ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (“Takeda”). The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver (...)
PARIS, France, 7:30 am (CET), October 16, 2018 – Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced positive topline results from its pivotal Phase 3 clinical trial (PLEO-CMT) evaluating two doses of PXT3003 compared to placebo during 15 months for the treatment of Charcot-Marie-Tooth type 1A disease (...)
At BIO Boston, the biocluster Genopole will encourage young French and international companies as well as young graduates with innovative biotech projects to apply for the third intake of its support programs Genopole has qualified for the French Tech visa program ; designed to attract talent to France and facilitate the arrival of investors, entrepreneurs and staff
Genopole - France’s leading biocluster - is a dynamic ecosystem where public and private synergies are cultivated to yield tomorrow’s scientific and industrial breakthroughs in biotech. This cluster will celebrate its 20th birthday and attend BIO International Convention on June 4-7, 2018 in Boston, booth #527. Read More ...
Global Bioenergies (Euronext Growth : ALGBE) announces today having been selected in three additional Horizon 2020 projects funded by the European Union, and will receive for this purpose about €2m in grants over 4 years. These projects reinforce Global Bioenergies’ strategy of feedstock diversification in order to continue improving the economics and the environmental impact of its Isobutene (...)
Global Bioenergies today announces the start of a 3-year project to demonstrate a new value chain combining its Isobutene process with technologies developed by Sekab and Neste Engineering Solutions, two of Europe’s leading technology developers. The aim is to convert currently poorly valorised softwood residues into second generation renewable isobutene for subsequent conversion into gasoline and jetfuel. A €13.9m grant agreement was signed with INEA on behalf of the European (...)
IntegraGen (FR0010908723 : ALINT - PEA-SME Eligible) (Paris:ALINT), a company specializing in the decoding of the human genome with a focus on producing interpretable genomic analyzes for academic and private laboratories and developing diagnostic tools in oncology, today announced that it has earned ISO 13485:2016 certification from Bureau Veritas. This certification indicates that the company’s quality management systems meet the specific standards required for the design, development, (...)
Global Bioenergies (GBE), the company developing a breakthrough process converting renewable resources into isobutene, and SkyNRG, world market leader in sustainable aviation fuel (SAF), will work together to accelerate the commercialization of Global Bioenergies’ approach to process isobutene into a jet fuel blending component. The companies will work towards the aviation industry’s approval allowing addition of Global Bioenergies’ isobutene-based SAF into ASTM D7566, the predominant jet fuel (...)
PEP-Therapy, Institut Curie and Gustave Roussy join together to conduct the Clever-Peptide project. It aims at the development of an innovative anti-cancer peptide, firstly for the treatment of triple-negative breast cancer, and its companion biomarker, predictive of treatment efficacy. Approved by the Medicen Paris Region cluster, this collaborative project obtains 2,9 M€ (...)